RingCentral Inc. Class A Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? RingCentral Inc. Class A Common Stock trades at $79.35 (market cap $6.54B), while State Street SPDR S&P Biotech ETF trades at $154.11 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and RingCentral Inc. Class A Common Stock pays a 0.35% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold RingCentral Inc. Class A Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| RNG | XBI | |
|---|---|---|
Market Cap | $6.54B | $10.11B |
Volume | 1,543,570 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $79.82 | $169.55 |
52-Week Low | $24.82 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $7.60B | — |
Dividend Yield | 0.35% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.
Read more on RNG →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →